These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 2451562)

  • 1. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
    Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V; Engert A; Schnell R; Vitetta ES
    Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
    Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
    Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
    Raso V; Ritz J; Basala M; Schlossman SF
    Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
    Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
    Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional evaluation of CD19- and CD22-negative variants of B-lymphoid cell lines.
    Kiesel S; Pezzutto A; Haas R; Moldenhauer G; Dörken B
    Immunology; 1988 Jul; 64(3):445-50. PubMed ID: 3261711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
    van Oosterhout YV; van den Herik-Oudijk IE; Wessels HM; de Witte T; van de Winkel JG; Preijers FW
    Cancer Res; 1994 Jul; 54(13):3527-32. PubMed ID: 7516821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
    Pietersz GA; Kanellos J; McKenzie IF
    Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
    Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA
    Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.